摘要
目的探讨阿卡波糖与伏格列波糖对2型糖尿病的临床疗效观察。方法 60例2型糖尿病患者,应用信封法随机分为试验组与对照组,每组30例。对照组患者口服伏格列波糖片治疗,试验组患者口服阿卡波糖片治疗,观察两组患者试验前后餐后2 h血糖、糖化血红蛋白及不良反应情况。结果治疗后,试验组患者餐后2 h血糖水平为(9.10±3.11)mmol/L,明显低于对照组的(11.80±3.68)mmol/L;试验组患者糖化血红蛋白为(6.00±0.63)%,低于对照组的(7.60±0.72)%,差异具有统计学意义(P<0.05)。试验组患者不良反应发生率为40.0%,高于对照组的16.67%,差异具有统计学意义(P<0.05)。结论采用阿卡波糖治疗的2型糖尿病患者餐后2 h血糖及糖化血红蛋控制效果优于采用伏格列波糖治疗的患者,但不良反应发生率高于伏格列波糖,临床可根据患者血糖变化及不良反应情况调整用药。
Objective To investigate clinical effect by acarbose and voglibose in the treatment of type 2 diabetes mellitus. Methods A total of 60 patients with type 2 diabetes mellitus were randomly divided into experimental group and control group, with 30 cases in each group. The control group received voglibose by oral administration for treatment, and the experimental group received acarbose by oral administration for treatment. Observation was made on 2 h postprandial blood glucose, glycosylated hemoglobin and adverse reactions before and after treatment in both groups. Results After treatment, the experimental group had obviously better 2 h postprandial blood glucose level as（9.10±3.11） mmol/L than（11.80±3.68） mmol/L in the control group. The experimental group had lower glycosylated hemoglobin as（6.00±0.63）% than（7.60±0.72）% in the control group, and the difference had statistical significance（P〈0.05）. The experimental group had higher incidence of adverse reactions as 40.0% than 16.67% in the control group, and the difference had statistical significance（P〈0.05）. Conclusion Implement of acarbose in treating type 2 diabetes mellitus patients provides better control effect of 2 h postprandial blood glucose and glycosylated hemoglobin than voglibose, while it shows higher incidence of adverse reactions than voglibose. Clinical medication can be adjusted in accordance with blood glucose changes and adverse reactions in patients.
出处
《中国现代药物应用》
2017年第1期129-131,共3页
Chinese Journal of Modern Drug Application
关键词
2型糖尿病
阿卡波糖
伏格列波糖
餐后血糖
不良反应
Type 2 diabetes mellitus
Acarbose
Voglibose
Postprandial blood glucose
Adverse reactions
